VEGFA and non-small cell lung carcinoma: Bevacizumab, a recombinant humanised anti-VEGF monoclonal antibody with a plasma half-life of approximately 3 weeks [21], was the first anti-angiogenic agent to show a survival benefit when combined with standard cytotoxic chemotherapy in advanced non-squamous NSCLC, extending median overall survival beyond 12 months [22].